Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Case Approach to Perioperative Drug-Drug InteractionsPharmacodynamic Interactions: Core Concepts

A Case Approach to Perioperative Drug-Drug Interactions: Pharmacodynamic Interactions: Core Concepts [This chapter discusses the essential terms and concepts pertaining to the relationship between the concentration of a drug at the end-organ site and the degree of drug effect. This subset of pharmacology is known as pharmacodynamics.] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

A Case Approach to Perioperative Drug-Drug InteractionsPharmacodynamic Interactions: Core Concepts

Editors: Marcucci, Catherine; Hutchens, Michael P.; Wittwer, Erica D.; Weingarten, Toby N.; Sprung, Juraj; Nicholson, Wayne T.; Lalwani, Kirk; Metro, David G.; Dull, Randal O.; Swide, Christopher E.; Seagull, F. Jacob; Kirsch, Jeffrey R.; Sandson, Neil B.
Wittwer, Erica D.; Nicholson, Wayne T.
A Case Approach to Perioperative Drug-Drug Interactions — May 7, 2013
Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/a-case-approach-to-perioperative-drug-drug-interactions-nqCE3ISZEz

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer New York
Copyright
© Springer Science+Business Media New York 2015
ISBN
978-1-4614-7494-4
Pages
9 –14
DOI
10.1007/978-1-4614-7495-1_2
Publisher site
See Chapter on Publisher Site

Abstract

[This chapter discusses the essential terms and concepts pertaining to the relationship between the concentration of a drug at the end-organ site and the degree of drug effect. This subset of pharmacology is known as pharmacodynamics.]

Published: May 7, 2013

Keywords: Pharmacodynamics; Pharmacokinetics; Absorption; Excretion; Metabolism; Distribution; Dose-response curve; Therapeutic window; Ligand-receptor interaction; Ligand affinity; Receptor affinity; Receptor specificity; Diphenhydramine; Efficacy; Toxicity; Ondansetron; 5-hydroxytryptamine 3 (5-HT 3 ) receptor; Agonism; Antagonism; Competitive binding; Partial agonist; Nondepolarizing neuromuscular blocking drugs; Acetylcholine receptors; Acetylcholinesterase; Nicotinic receptor; Muscarinic receptor; Ceiling effect; Cholinesterase inhibitor; Phenoxybenzamine; Ligand-gated ion channels; G protein–coupled receptors; Enzyme-linked receptors; Intracellular receptors; Opioid receptor (μυ οπιοιδ ρεχεπτορ, καππα οπιοιδ ρεχεπτορ, δ opioid receptor; Substance P; Dopamine; Serotonin; Histamine 1 (H 1 ); Cannabinoid; γ-aminobutyric acid B receptors; GABA B NMDA receptors. Enzyme-linked natriuretic peptide receptor; Epidermal growth factor receptor. Estrogen receptor; Mineralocorticoid receptor; Thyroid hormone receptors; Tolerance; Drug tolerance; Cross-tolerance; Addiction; Dependance; Tachyphylaxis; Transdermal nitroglycerin; Synergy; Additive drug interaction; Antagonistic drug interaction; Infra-additive drug interaction; Isoflurane; Nitrous oxide

There are no references for this article.